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Abstract
Background: Haploinsufficiency of the runt-related transcription factor 2 (RUNX2) gene is known to cause cleidocranial
dysplasia (CCD). Here, we investigated a complex, heterozygous RUNX2 gene mutation in a Chinese family with CCD
and the pathogenesis associated with the variations.
Methods: Genomic DNA extracted from peripheral venous blood was taken from the proband, her parents and 3
siblings, and 150 normal controls. Analysis of their respective RUNX2 gene sequences was performed by PCR
amplification and Sanger sequencing. Pathogenesis associated with RUNX2 mutations was investigated by
performing bioinformatics, real-time PCR, western blot analysis, and subcellular localization studies.
Results: We identified 2 complex heterozygous mutations involving a c.398–399 insACAGCAGCAGCAGCA insertion
and a c.411–412 insG frameshift mutation in exon 3 of the RUNX2 gene. The frameshift mutation changed the
structure of the RUNX2 protein while did not affect its expression at the mRNA level. Transfection of HEK293T cells with
a plasmid expressing the RUNX2 variant decreased the molecular weight of the variant RUNX2 protein, compared with
that of the wild-type protein. Subcellular localization assays showed both nuclear and cytoplasmic localization for the
mutant protein, while the wild-type protein localized to the nucleus.
Conclusions: Our findings demonstrated that the novel c.398–399insACAGCAGCAGCAGCA mutation occurred
alongside the c.411–412insG frameshift mutation, which resulted in RUNX2 truncation. RUNX2 haploinsufficiency was
associated with CCD pathogenesis. These results extend the known mutational spectrum of the RUNX2 gene and
suggest a functional role of the novel mutation in CCD pathogenesis.
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Background
Cleidocranial dysplasia (CCD, OMIM 119600) is an
autosomal dominant human skeletal disorder resulting
from haploinsufficiency of the Runt-related transcription
factor 2 (RUNX2) gene, a master regulator for bone and
cartilage development and maintenance [1–6]. CCD is
characterized by a myriad of skeletal abnormalities and
short stature. Skeletal abnormalities associated with
CCD include hypoplastic or aplastic clavicles, patent
sutures and fontanelles, dental abnormalities, and other
skeletal abnormalities [2, 7, 8].
RUNX2 haploinsufficiency causes CCD and, al-
though most CCD patients have a family history of
CCD, approximately one-third of CCD patients were
found to lack RUNX2 mutations [4, 9]. Here, we inves-
tigated a Chinese patient with CCD and identified 2
complex heterozygous RUNX2 mutations. To investi-
gate the function and potential pathogenic mechanism
of the RUNX2 mutant, we performed bioinformatics,
real-time PCR, western blot analysis, and subcellular
localization studies. Our results suggested that the
novel mutations changed the molecular weight, struc-
ture, nuclear localization, and expression of the
RUNX2 protein.
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The proband (patient II-1), a 17-year-old girl, was re-
ferred to the Department of Stomatology at Nanfang
Hospital for consultation regarding a dental abnormality.
An experienced pediatric dentist performed clinical ex-
aminations for the proband and her family. Medical his-
tories were obtained from the family members,
including her parents and 3 siblings. One hundred and
fifty normal controls from healthy individuals matched
for gender and ethnic origin were recruited from Nan-
fang Hospital in Guangzhou, Guangdong. All subjects
gave informed consent and the study was approved by
the Ethics Committee of Southern Medical University.
RUNX2-gene mutation screening
To identify disease-associated mutations, we extracted
genomic DNA from the peripheral blood of the proband
and her family members by a standard phenol/chloroform
extraction method. PCR reactions were performed using
primers designed with Primer3 plus software, the se-
quences of which are shown in Table 1. The PCR products
were visualized by 1.5% agarose gel electrophoresis and
subsequently analyzed by Sanger sequencing.
To identify RUNX2 (NCBI Reference Sequence:
NM_001015051.3) gene mutations, PCR products corre-
sponding to exon 3 of RUNX2 were cloned into the
PMD-18 T vector (TaKaRa Biotechnology, Dalian, Co.,
Ltd) and introduced into DH5α bacteria (TaKaRa Bio-
technology). Transformants were then isolated, and the
RUNX2 gene sequences were studied by PCR and DNA
sequencing.
RNA analysis
Total RNA was extracted from the peripheral blood of
the proband and her parents with TRIzol (Invitrogen,
Carlsbad, CA, USA) and purified by chloroform extrac-
tion and isopropanol precipitation. Total RNA samples
were quantified by measuring the absorbance at 260 and
280 nm. Reverse transcriptase-polymerase chain reac-
tions (RT-PCR) were performed using the PrimeScript
RT-PCR Kit (TaKaRa Biotechnology). Quantitative RT-
PCR (qRT-PCR) was performed to compare peripheral
blood RUNX2 mRNA expression levels between the pa-
tient and her parents. qRT-PCR was performed using
Platinum SYBR Green (Bio-Rad Laboratories, California,
USA) and an MxPro Real-Time PCR System (Stratagene
MX3005P), using 40 cycles of 95 °C for 20 s, 63 °C for
20 s, and 72 °C for 20 s. The sequences of the primers
used for the qRT-PCR experiments are shown in Table 2.
Each sample was analyzed in triplicate, and β-actin
mRNA expression was measured as a reference. Stu-
dent’s 2-tailed t-test was used for statistical analysis.
Bioinformatics
Three-dimensional structures of the wild-type and mu-
tant RUNX2 protein were predicted using the I-TASSER
server [10, 11].
Construction of recombinant plasmids
PCR fragments encoding the mutant or wild-type
RUNX2 gene were amplified using primers designed by
Oligo 7 (sequences shown in Table 3) to have an anneal-
ing temperature of 63 °C. The PCR products were ex-
tracted from a 1.5% agarose gel using the SanPrep
Column DNA Gel Extraction Kit (Sangon Biotech,
Shanghai). The purified PCR product for the mutant
gene was then cloned into the PMD-20 T vector
(TaKaRa Biotechnology) to generate the PMD-20 T-
RUNX2 mutant construct. After sequence confirmation,
the inserted mutant RUNX2 gene was then subcloned
into the pEGFP-C1 vector via the SalI and XamI restric-
tion sites, generating a recombinant plasmid (pEGFP-
C1-RUNX2) encoding the mutant RUNX2 gene. A re-
combinant plasmid encoding the wild-type RUNX2 gene
was constructed using the same method.
Western blot analysis
To study protein expression, recombinant plasmids en-
coding wild-type or mutant RUNX2 templates, as well
as the parental vector (pEGFP-C1), were transfected sep-
arately into human embryonic kidney (HEK) 293 T cells.
After 24 h in culture, total proteins were extracted with
cell lysis buffer for western blotting (Beyotime, Shang-
hai) containing of Protease Inhibitor Cocktail (Sigma, St.
Louis, MO). The proteins were resolved by sodium do-
decyl sulfate-polyacrylamide gel electrophoresis. The
separated proteins were transferred to polyvinylidene
Table 1 Primers used in RUNX2polymerase chain reaction (PCR)




Exon 1 AGAGAGAGAAAGAGCAAGGGG GCATAGACTGTGGTTAGAGAGC
Exon 2 TTTCTTTGCTTTTCACATGTTACC TGCTATTTGGAAAAGCTAGCAG
Exon 3 CGCTAACTTGTGGCTGTTGT CGTGGGCAGGAAGACACC
Exon 4 CATTCCTGTCGGCCATTACTG CATCAAAGGAGCCTAATGTGCT
Exon 5 AAGTGGTCATCGGAGGGTTT TGCAGATAGCAAAGTCCACAA
Exon 6 GGCCACCAGATACCGCTTAT CCAGCGTCTATGCAAGTGAA
Exon 7 GCCTGAAAGGATGGGGTTAT CTGTGCAGGGATGGATTTTT
Exon 8 CTTATGGGCCTGCAGACTCT AGTAACAACCAGACAGCCCA
Exon 9 CTGTGGCTTGCTGTTCCTTT TGATACGTGTGGGATGTGGC
Table 2 Primers used for qRT-PCR
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difluoride membranes (Millipore). After the membranes
were blocked in TBST containing 5% non-fat milk, they
were incubated overnight with a primary antibody
against enhanced green fluorescence protein (Santa Cruz
Biotechnology, USA). Next, the membranes were incu-
bated for 2 h with an appropriate secondary antibody
(Santa Cruz Biotechnology) at room temperature. Rela-
tive RUNX2 protein expression levels were calculated
after normalization to glyceraldehyde 3-phosphate de-
hydrogenase (Santa Cruz Biotechnology) expression.
Protein expression was detected using the Immobilon
Western Chemiluminescent HRP Substrate (Thermo
Fisher, USA).
Cell localization studies
Recombinant plasmids encoding wild-type or mutant
RUNX2 genes were transfected into COS7 cells to study
the subcellular localization of the RUNX2 protein and
the impact of the mutation. At 48 h post-transfection,
cells were rinsed 3 times with PBS, and nuclei were
stained with 0.1 μg/ml 4′,6-diamidino-2-phenylindole
(Sigma) for 10 min at room temperature. Subsequently,
the cells were viewed under an Eclipse Ti-U fluorescence
microscope (Nikon; Tokyo, Japan).
Results
Clinical features of the proband patient
The patient underwent a detailed clinical evaluation by
an experienced dentist. Physical examination revealed
short stature (height: 143 cm), dental abnormalities, a
high-arched palate, open fontanelles, and ptotic and
hypermobile shoulders. The remaining clinical features
tested for were normal. The family history and physical
examinations revealed no other family members with
bony abnormalities.
Detailed dental abnormalities, including impacted
supernumerary teeth, retention of primary teeth,
eruption failure of permanent teeth, and abnormal
root development were very instructive for devising a
treatment plan (Fig. 1a, b). Delayed closure of the
cranial sutures and detailed dental abnormalities were
identified by computed tomography (Fig. 1c, d). Chest
radiographs showed hypoplastic or aplastic clavicles
and structural abnormalities of the right shoulder-
peak joint (Fig. 1e). The overall characteristics of the
clinical and radiographic results supported a clinical
diagnosis of CCD.
Sequence analysis of RUNX2 gene
All 9 coding exons of the RUNX2 gene were amplified
by PCR. Direct screening revealed complex mutations in
exon 3 of the patient’s gene, which were not identified in
the parents’ DNA (Fig. 2b). Thus, these mutations arose
de novo, as neither parent carried these mutations, and
non-paternity was excluded by paternity testing.
BLAST analysis revealed novel mutations (c.398–399
insACAGCAGCAGC AGCA and c.411–412insG) in cis
in the runt domain of the patient’s RUNX2 gene (Fig. 2c,
d). The insertions created a frameshift mutation that led
to the translated nornal proteins changing into truncated
proteins containing 165 amino proteins. Both mutations
were absent in DNA samples from 150 unrelated, nor-
mal control subjects that were matched for Chinese eth-
nicity to rule out the possibility of these mutations
occurring naturally as single-nucleotide polymorphisms.
Functional analysis
Our qRT-PCR results showed that the patient’s RUNX2
messenger RNA expression level was not significantly
different from those of her parents (Fig. 3a). However,
western blot analysis revealed that transfection with a
wild-type RUNX2 construct resulted in the production
of a 56-kDa protein, whereas transfection with the mu-
tant RUNX2 construct produced an 18-kDa, truncated
protein (Fig. 3b). These molecular masses matched the
expected sizes of the encoded RUNX2 variants. Three-
dimensional structures predicted with the I-TASSER ser-
ver showed the anticipated structural changes resulting
from the RUNX2, exon 3 mutations (Fig. 3d).
The exon 3 mutations affected subcellular location of
the RUNX2 variant. The mutant protein expressed from
the pEGFP-C1-RUNX2 plasmid was distributed
throughout both the cytoplasm and nucleus of trans-
fected COS7 cells, whereas the wild-type protein was lo-
calized only in the nucleus (Fig. 3c).
Discussion
Mutations in the RUNX2 gene, that maps to the short
arm of chromosome 6, cause CCD [12]. The RUNX2
gene encodes a transcription factor that is a member of
the core-binding factor family. In this report, we present
data from a patient with a novel in-frame insertion mu-
tation in the RUNX2 gene and CCD symptoms, such as
disproportionate short stature and the classic triad of
multiple supernumerary teeth, open sagittal sutures and
fontanelles, and hypoplastic or aplastic clavicles [13, 14].
Apart from these typical clinical features, CCD patients
can show other symptoms, such as mental deficiencies,
hearing disorders, median pseudo-cleft palates, delayed
ossification of the pelvis, and other skeletal abnormal-
ities [15–17]. CCD is an autosomal dominant genetic
disease; thus, patient’s parents generally harbor the same
Table 3 Primers designed by oligo 7
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genetic mutation, although patients with unaffected par-
ents have been reported in several studies [4, 9, 13]. In
this study, insertional mutations were found in exon 3 of
the patient’s RUNX2 gene, while her parents lacked
these mutations. Paternity testing excluded the non-
paternity between the proband and her parents, thereby
indicating that the genetic abnormalities arose as de
novo events. We propose that the de novo mutations
should have arisen during the spermatogenic process or
an early stage in embryonic development.
Although CCD-related bone anomalies develop
through an unclear mechanism(s), it is known that CCD
results from RUNX2-dependent signaling pathways. The
RUNX2 protein regulates extracellular matrix properties
and mineralization through transforming growth factor-
β-responsive, COL10A1, VEGF, and MMP13 pathways,
providing supporting evidence that RUNX2 affects endo-
chondral ossification, intramembranous ossification, and
chondrocyte maturation [16, 18, 19]. The RUNX2 pro-
tein forms a complex with core-binding factor β (CBFβ)
and binds to a conserved nucleotide sequence (R/
TACCRCA) to drive expression of several osteogenic
proteins, such as collagen a1, osteopontin, bone sialo-
protein, and osteocalcin [20, 21]. Collectively, these find-
ings indicate that RUNX2 plays an important role in
osteoblast differentiation. Periodontal ligament stem
cells modulate root resorption in human primary teeth
via the RUNX2-regulating, receptor activator of nuclear
factor kappa-B ligand pathway, causing the retention of
primary teeth [22]. The RUNX2 protein can be thought
of as having 4 domains, consisting of the N terminus,
the runt domain, the PST domain, and the C terminus.
Fig. 1 Radiological findings for the patient. a, b Cone-beam computed tomography results showing detailed dental abnormalities, including
impacted supernumerary teeth, the retention of primary teeth, eruption failure of the permanent teeth, and impaired root development.
c, d A skull CT scan showed the presence of open fontanelles. e Radiographs revealed hypoplastic or aplastic distal ends of clavicles and structural
abnormalities occurring in the right shoulder peak joint
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Fig. 2 Mutation analysis. a Family pedigree. The arrow indicates the proband in the family. b Mutation screening. Sequences of the wild-type
(WT) and mutant (MUT) RUNX2 gene sequences occurring in exon 3. Nucleotides highlighted in the red boxes show the insertion mutations.
c Forward DNA sequencing results. Panels I-1 and I-2 show the sequences of wild-type RUNX2 alleles, and panel II-1 shows double peaks within
this region. d Reverse DNA sequencing results. Panels I-1 and I-2 show sequences of WT RUNX2 alleles, and panel II-1 shows a
double-peak phenomenon
Fig. 3 Functional analysis of wild-type and mutant RUNX2. a Quantification of RUNX2 mRNA expression levels revealed no significant difference
(P = 0.6218) between the patient and her parents. b Western blot analysis of RUNX2 protein expression showed that transfection of the wild-type
RUNX2 construct resulted in full-length RUNX2 protein production, whereas overexpression of mutant RUNX2 generated a truncated protein.
GAPDH, 37 kDa. c COS7 cells were transfected with recombinant plasmids encoding the wild-type or mutant RUNX2 genes. Confocal micrographs
showed the intracellular distributions of the wild-type and mutant RUNX2 proteins. d Molecular modeling performed using the I-TASSER server
revealed that the mutant runt domain plays a critical role in the normal 3-dimensional structure of RUNX2, as indicated
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The runt domain and nuclear localization signal (NLS)
at the C-terminal domain border is important for the
transcriptional activity, subcellular distribution, and ag-
gregation of the RUNX2 protein [23–25]. Furthermore,
many findings have revealed that the runt domain is re-
sponsible for DNA binding and heterodimerization with
the CBFβ protein [3, 4] The CBFβ protein is an unre-
lated binding partner that enhances the DNA-binding
affinity of the RUNX2 protein [26].
In the present study, the patient showed normal
RUNX2 mRNA expression compared with her parents,
which indicated that the mutation did not affect mRNA
transcription. However, the insertional mutation occur-
ring in the patient led to premature translation termin-
ation, producing a truncated protein containing 165
amino proteins. Structural modeling suggested that the
normal molecular structure of the truncated protein was
altered, thereby abolishing the function of the runt do-
main, which could also redirect nuclear RUNX2 from
the nucleus to the cytoplasm to prevent binding to CBFβ
[24, 25]. In addition, the truncated protein lost the NLS,
which is normally present at the C-terminal border. This
alteration could impair the transcriptional activation
function of RUNX2, resulting in decreased ossification
and skeletal deformities [1, 23].
Conclusions
Haploinsufficiency of the RUNX2 gene is known to be
the reason of CCD. Here, we present a molecular cyto-
genetic characterization of novel RUNX2 insertional mu-
tations occurring in a 17-year-old female patient with
CCD and discuss potential genotype–phenotype correla-
tions in this case. Data presented here expand the
known RUNX2 mutation spectrum and potentially shed
insight into the development of CCD.
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